Genomes and Genes
Summary: Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
Publications321 found, 100 shown here
- Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South AfricaStephen D Lawn
Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
AIDS 21:335-41. 2007..To determine the burden and impact of immune reconstitution disease (IRD) associated with tuberculosis (TB) among patients initiating antiretroviral treatment (ART) in sub-Saharan Africa...
- The challenge of new drug discovery for tuberculosisAnil Koul
Department of Antimicrobial Research, Janssen Research and Development, Johnson and Johnson, Turnhoutseweg 30, B 2340 Beerse, Belgium
Nature 469:483-90. 2011..In this review, we discuss innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients...
- Rapid molecular detection of tuberculosis and rifampin resistanceCatharina C Boehme
Foundation for Innovative New Diagnostics, Geneva, Switzerland
N Engl J Med 363:1005-15. 2010..Early detection is essential to reduce the death rate and interrupt transmission, but the complexity and infrastructure needs of sensitive methods limit their accessibility and effect...
- Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technologyDanica Helb
Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey 07103, USA
J Clin Microbiol 48:229-37. 2010..2%) susceptible cases. Specificity rose to 100% after correcting for a conventional susceptibility test error. In conclusion, this highly sensitive and simple-to-use system can detect M. tuberculosis directly from sputum in less than 2 h...
- Timing of antiretroviral therapy for HIV-1 infection and tuberculosisDiane V Havlir
University of California, San Francisco, 995 Potrero Ave, Bldg 80, Ward 84, San Francisco, CA 94110 2897, USA
N Engl J Med 365:1482-91. 2011....
- Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosisFrancois Xavier Blanc
Pneumology Unit, Internal Medicine Department, Bicetre Hospital, Assistance Publique Hopitaux de Paris, Le Kremlin Bicetre, France
N Engl J Med 365:1471-81. 2011..Robust data are lacking with regard to the timing for the initiation of antiretroviral therapy (ART) in relation to the start of antituberculosis therapy...
- Integration of antiretroviral therapy with tuberculosis treatmentSalim S Abdool Karim
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
N Engl J Med 365:1492-501. 2011..We previously reported that integrating antiretroviral therapy (ART) with tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during tuberculosis treatment remains unresolved...
- Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence settingGrant Theron
Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa
Am J Respir Crit Care Med 184:132-40. 2011..Xpert MTB/RIF is a novel automated molecular diagnostic recently endorsed by the World Health Organization. However, performance-related data from high HIV prevalence settings are limited...
- Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosisNeel R Gandhi
Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY 10467, USA
Lancet 375:1830-43. 2010....
- HIV infection and multidrug-resistant tuberculosis: the perfect stormCharles D Wells
Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
J Infect Dis 196:S86-107. 2007..The global human immunodeficiency virus (HIV) infection epidemic has caused explosive increases in TB incidence and may be contributing to increases in MDR-TB prevalence...
- The population dynamics and control of tuberculosisChristopher Dye
World Health Organization, CH1211 Geneva 27, Switzerland
Science 328:856-61. 2010..Whatever the technology used, success depends critically on the social, institutional, and epidemiological context in which it is applied...
- Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance SurveillanceAbigail Wright
Stop TB Department, WHO, Geneva, Switzerland
Lancet 373:1861-73. 2009..The Global Project on Anti-Tuberculosis Drug Resistance has been gathering data since 1994. This study provides the latest data on the extent of drug resistance worldwide...
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosisHenry M Blumberg
Am J Respir Crit Care Med 167:603-62. 2003
- Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control studyBernard N Muture
National Public Health Laboratory Services, Ministry of Health, PO Box 20750 00202, Nairobi, Kenya
BMC Public Health 11:696. 2011..Kenya is among countries with high tuberculosis burden globally. The purpose of this study was to determine the duration tuberculosis patients stay in treatment before defaulting and factors associated with default in Nairobi...
- Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patientsShama D Ahuja
Bureau of Tuberculosis, New York, New York, United States of America
PLoS Med 9:e1001300. 2012..We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB...
- The HIV-associated tuberculosis epidemic--when will we act?Anthony D Harries
International Union Against Tuberculosis and Lung Disease, Paris, France
Lancet 375:1906-19. 2010..The continuing HIV-associated tuberculosis epidemic needs bold but responsible action, without which the future will simply mirror the past...
- A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosisKoen Andries
Johnson and Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium
Science 307:223-7. 2005..Plasma levels associated with efficacy in mice were well tolerated in healthy human volunteers. Mutants selected in vitro suggest that the drug targets the proton pump of adenosine triphosphate (ATP) synthase...
- Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010Matteo Zignol
Stop TB Department, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland
Bull World Health Organ 90:111-119D. 2012..To present a global update of drug-resistant tuberculosis (TB) and explore trends in 1994-2010...
- Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugsPedro Eduardo Almeida Almeida Da Silva
Laboratory of Tuberculosis, Faculty of Medicine, Universidade Federal do Rio Grande FURG, Brazil
J Antimicrob Chemother 66:1417-30. 2011..tuberculosis...
- Mechanisms of drug resistance in Mycobacterium tuberculosisY Zhang
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
Int J Tuberc Lung Dis 13:1320-30. 2009..Understanding the mechanisms of drug resistance in M. tuberculosis would enable the development of rapid molecular diagnostic tools and furnish possible insights into new drug development for the treatment of TB...
- WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 updateD Falzon
Stop TB Dept, World Health Organization, Geneva 27, Switzerland
Eur Respir J 38:516-28. 2011..Controlled trials are needed to improve the quality of existing evidence, particularly on the optimal composition and duration of MDR-TB treatment regimens...
- Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysisEvan W Orenstein
Tugela Ferry Care and Research Collaboration, Tugela Ferry, KwaZulu Natal, South Africa
Lancet Infect Dis 9:153-61. 2009..These results underscore the importance of strong patient support and treatment follow-up systems to develop successful MDR tuberculosis treatment programmes...
- The impact of diabetes on tuberculosis treatment outcomes: a systematic reviewMeghan A Baker
Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
BMC Med 9:81. 2011..We performed a systematic review and meta-analysis to quantitatively summarize evidence for the impact of diabetes on tuberculosis outcomes...
- Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosisJose A Caminero
Servicio de Neumologia, Hospital General de Gran Canaria, Las Palmas, Canary Islands, Spain
Lancet Infect Dis 10:621-9. 2010..Drugs in group five should be used in the following order: clofazimine, amoxicillin with clavulanate, linezolid, carbapenems, thioacetazone, then clarithromycin...
- Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosisPayam Nahid
Curry International Tuberculosis Center, University of California, San Francisco, CA, USA
BMC Infect Dis 11:1. 2011..Tuberculosis is a leading cause of death worldwide, yet the determinants of death are not well understood. We sought to determine risk factors for mortality during treatment of drug-susceptible pulmonary tuberculosis under program settings...
- SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosisKapil Tahlan
Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA
Antimicrob Agents Chemother 56:1797-809. 2012..Our results suggest that MmpL3 is the target of SQ109 and that MmpL3 is a transporter of mycobacterial TMM...
- Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosisPatricia J Campbell
Mycobacteriology Laboratory Branch, Division of Tuberculosis Elimination, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Bldg 17, Room 4029, M S F08, Atlanta, GA 30333, USA
Antimicrob Agents Chemother 55:2032-41. 2011..tuberculosis complex. Further, the results can be used to design diagnostic tests utilizing other mutation detection technologies...
- Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practiceRobert S Wallis
Pfizer, New London, CT, USA
Lancet 375:1920-37. 2010..Translation of scientific progress in biomarkers and diagnostics into clinical and public health programmes is possible-with political commitment, increased funding, and engagement of all stakeholders...
- Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsGraeme Meintjes
Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa
Lancet Infect Dis 8:516-23. 2008..It is envisaged that these definitions could be used by clinicians and researchers in a variety of settings to promote standardisation and comparability of data...
- Paediatric tuberculosisSandra M Newton
Department of Paediatrics, Imperial College London, London, UK
Lancet Infect Dis 8:498-510. 2008..Advances in our understanding of tuberculosis in children would provide insights and opportunities to enhance efforts to control this disease...
- A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisC K Stover
PathoGenesis Corporation, Seattle, Washington 98119, USA
Nature 405:962-6. 2000..tuberculosis and promising oral activity in animal infection models. We conclude that nitroimidazopyrans offer the practical qualities of a small molecule with the potential for the treatment of tuberculosis...
- Tuberculosis: what we don't know can, and does, hurt usDavid G Russell
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
Science 328:852-6. 2010..Here we focus on the biology of the host-pathogen interaction and discuss new and evolving strategies for intervention...
- Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South AfricaJames C M Brust
Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of America
PLoS ONE 6:e15841. 2011..We describe culture conversion rates among MDR-TB patients with and without HIV-co-infection in a TB-endemic, high-HIV prevalent, resource-limited setting...
- Fueling open-source drug discovery: 177 small-molecule leads against tuberculosisLluis Ballell
Tres Cantos Medicines Development Campus TCMDC, GlaxoSmithKline GSK, Severo Ochoa 2, Tres Cantos, Madrid, Spain
ChemMedChem 8:313-21. 2013..Two additional drug-discovery-relevant datasets are included: a) a drug-like property analysis reflecting the latest lead-like guidelines and b) an early lead-generation package of the most promising hits within the clusters identified...
- Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort studyTracy Dalton
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Lancet 380:1406-17. 2012..We prospectively assessed resistance to second-line antituberculosis drugs in eight countries...
- Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisDaphne Yee
Respiratory Epidemiology Unit, Montreal Chest Institute, 1110 Pine Avenue West, Room 103, Montreal, PQ, H3A 1A3 Canada
Am J Respir Crit Care Med 167:1472-7. 2003..0; 95% CI, 1.5 to 43). The incidence of pyrazinamide-induced hepatotoxicity and rash during treatment for active TB was substantially higher than with the other first-line anti-TB drugs, and higher than previously recognized...
- Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosisWei Lun Huang
Reference Laboratory of Mycobacteriology, Research and Diagnostic Center, Centers for Disease Control, Taipei, Taiwan, Republic of China
J Clin Microbiol 49:2502-8. 2011..We recommend including new alleles consisting of the eis promoter and embB genes in molecular analysis. However, conventional DST is necessary to rule out false-negative results from molecular assays...
- Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countriesM A Espinal
World Health Organization, Communicable Diseases Programme, Ave Appia 20, 1211 Geneva 27, Switzerland
JAMA 283:2537-45. 2000....
- Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesisVadim Makarov
A N Bakh Institute of Biochemistry, Russian Academy of Science, 119071 Moscow, Russia
Science 324:801-4. 2009..The most advanced compound, BTZ043, is a candidate for inclusion in combination therapies for both drug-sensitive and extensively drug-resistant TB...
- 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trialTaraz Samandari
Botswana USA Partnership BOTUSA, Gaborone and Francistown, Botswana
Lancet 377:1588-98. 2011..We aimed to assess effectiveness of extended isoniazid therapy...
- The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy eraB J Marais
Centre for TB Research and Education, Stellenbosch University, Cape Town, Western Cape, South Africa
Int J Tuberc Lung Dis 8:392-402. 2004..Deciding which children to treat may be extremely difficult in high-prevalence, low-resource settings. The concept of relevant disease provides guidance for more effective public health intervention...
- An official ATS statement: hepatotoxicity of antituberculosis therapyJussi J Saukkonen
Am J Respir Crit Care Med 174:935-52. 2006..Priorities for future studies to develop safer treatments for LTBI and for TB disease are presented...
- The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem studyTed Cohen
Division of Global Health Equity, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS Med 7:e1000296. 2010..We conducted limited autopsies on young adults dying in a single public hospital in the province of KwaZulu-Natal between October 2008 and August 2009 in order to estimate the magnitude of deaths attributable to tuberculosis...
- Comprehensive treatment of extensively drug-resistant tuberculosisCarole D Mitnick
Harvard Medical School, Boston, USA
N Engl J Med 359:563-74. 2008..We describe the management of extensively drug-resistant tuberculosis and treatment outcomes among patients who were referred for individualized outpatient therapy in Peru...
- Facing the crisis: improving the diagnosis of tuberculosis in the HIV eraMark D Perkins
Foundation for Innovative New Diagnostics, Geneva, Switzerland
J Infect Dis 196:S15-27. 2007..In this article, we will define the need for better TB tests and describe technologies being developed to meet that need...
- Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis controlSurendra K Sharma
Division of Pulmonary and Critical Care Medicine, Department of Medicine, All India Institute of Medical Sciences, New Delhi 110 029, India
Chest 130:261-72. 2006..With newer effective anti-TB drugs still a distant dream, innovative approaches such as DOTS-Plus are showing promise for the management of patients with MDR-TB under program conditions and appear to be a hope for future...
- Delamanid for multidrug-resistant pulmonary tuberculosisMaria Tarcela Gler
Makati Medical Center, Manila, Philippines
N Engl J Med 366:2151-60. 2012....
- Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iranAli Akbar Velayati
Mycobacteriology Research Centre, the National Research Institute of Tuberculosis and Lung Disease, World Health Organization Collaborating Centre, Shahid Beheshti University, Darabad, Tehran, Iran
Chest 136:420-5. 2009..The study documented the emergence of new forms of resistant bacilli (totally drug-resistant [TDR] or super extensively drug-resistant [XDR] tuberculosis [TB] strains) among patients with multidrug-resistant TB (MDR-TB)...
- Challenges and opportunities in developing novel drugs for TBTakushi Kaneko
TB Alliance, 40 Wall Street, 24th Floor, New York, NY 10005, USA
Future Med Chem 3:1373-400. 2011..In this perspective we will focus on the early discovery phases of drug development and try to provide snapshots of both the current status and future prospects...
- Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosisJoaquín Rullas
GlaxoSmithKline, Infectious Diseases Centre of Excellence in Drug Discovery, Diseases of the Developing World, Madrid, Spain
Antimicrob Agents Chemother 54:2262-4. 2010..This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin...
- Epidemiology and clinical management of XDR-TB: a systematic review by TBNETG Sotgiu
Hygiene and Preventive Medicine Institute, University of Sassari, Sassari, Italy
Eur Respir J 33:871-81. 2009..Early diagnosis and aggressive management of extensively drug-resistant tuberculosis provide the best chance of positive outcome, but prevention is still paramount...
- New and improved diagnostics for detection of drug-resistant pulmonary tuberculosisJustin O'Grady
Department of Infection, University College London Medical School, Windeyer Institute of Medical Sciences, 46 Cleveland Street, London, UK
Curr Opin Pulm Med 17:134-41. 2011..During the past decade, there have been significant advances in diagnostic technologies for TB and drug-resistant TB. The purpose of this article is to review the current data, recommendations and evidence base for these tests...
- High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37RvRobert C Reynolds
Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
Tuberculosis (Edinb) 92:72-83. 2012....
- Timing of initiation of antiretroviral drugs during tuberculosis therapySalim S Abdool Karim
Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa
N Engl J Med 362:697-706. 2010..The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial...
- Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South AfricaMarinus Barnard
Foundation for Innovative New Diagnostics, 71 av Louis Casai, 1216 Cointrin, Switzerland
Am J Respir Crit Care Med 177:787-92. 2008..Conventional methods for detecting Mycobacterium tuberculosis drug resistance take weeks to months to produce results. Rapid molecular testing for drug resistance is available but has not been implemented in high-TB-burden settings...
- Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of viewCarleitta Paige
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Cell Microbiol 12:301-9. 2010..Host-directed therapy that alters the immune response may offer an alternative approach towards reducing treatment duration, the risk of anti-microbial resistance and improving patient outcome...
- Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primatesLaura E Via
Tuberculosis Research Section, Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20852, USA
Infect Immun 76:2333-40. 2008..Thus, three independent lines of evidence support the hypothesis that hypoxic microenvironments are an important feature of some lesions in these animal models of tuberculosis...
- Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasisAnil Koul
Departments of Antimicrobial Research and Functional Genomics, Johnson and Johnson, Turnhoutseweg 30, B 2340 Beerse, Belgium
J Biol Chem 283:25273-80. 2008....
- Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South AfricaThomas R Ioerger
Department of Computer Science and Engineering, Texas A and M University, College Station, Texas, United States of America
PLoS ONE 4:e7778. 2009....
- High-throughput screening for inhibitors of Mycobacterium tuberculosis H37RvSubramaniam Ananthan
Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
Tuberculosis (Edinb) 89:334-53. 2009There is an urgent need for the discovery and development of new antitubercular agents that target new biochemical pathways and treat drug resistant forms of the disease...
- Mycobacterium tuberculosis: here today, and here tomorrowD G Russell
Microbiology and Immunology, 5173 Veterinary Medical Center, Cornell University, Ithaca, New York 14853, USA
Nat Rev Mol Cell Biol 2:569-77. 2001..As the macrophage is key to clearing the infection, the interplay between the pathogen and its host cell reflects a constant battle for control...
- Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000T Santha
Tuberculosis Research Centre, Chetput, Chennai, India
Int J Tuberc Lung Dis 6:780-8. 2002..To identify risk factors associated with default, failure and death among tuberculosis patients treated in a newly implemented DOTS programme in South India...
- OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in miceMakoto Matsumoto
Microbiological Research Institute, Otsuka Pharmaceutical, Tokushima, Japan
PLoS Med 3:e466. 2006..Global health and philanthropic organizations are now pleading for new drug interventions that can address these unmet needs in TB treatment...
- International standards for tuberculosis carePhilip C Hopewell
Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
Lancet Infect Dis 6:710-25. 2006....
- Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitisM Estee Torok
Department of Infectious Diseases, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom
Clin Infect Dis 52:1374-83. 2011..The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-associated tuberculous meningitis is unknown...
- Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysisWoojin Lew
Montreal Chest Institute, McGill University, Montreal, Quebec, Canada
Ann Intern Med 149:123-34. 2008..Despite the increasing prevalence of drug-resistant tuberculosis, most low- and middle-income countries use standardized regimens, without assessment of drug susceptibility...
- Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosisSusan E Dorman
Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland 21231, USA
Am J Respir Crit Care Med 180:273-80. 2009..Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited...
- Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosisWanliang Shi
W Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
Science 333:1630-2. 2011..Trans-translation is essential for freeing scarce ribosomes in nonreplicating organisms, and its inhibition may explain the ability of PZA to eradicate persisting organisms...
- European union standards for tuberculosis careG B Migliori
WHO Collaborating Centre for TB and Lung Diseases, Fondazione S Maugeri, Care and Research Institute, via Roncaccio 16, 21049 Tradate, Italy
Eur Respir J 39:807-19. 2012..These will support EU health programmes to identify and develop optimal procedures for TB care, control and elimination...
- Community-based therapy for multidrug-resistant tuberculosis in Lima, PeruCarole Mitnick
Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, MA 02115, USA
N Engl J Med 348:119-28. 2003..We evaluated the results of community-based therapy for multidrug-resistant tuberculosis in a poor section of Lima, Peru...
- Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohortJonathan E Golub
Johns Hopkins University, School of Medicine, 1550 Orleans St, 1M 07 Baltimore, MD 21231, USA
AIDS 23:631-6. 2009..There is less information on the combined effect of IPT and HAART. We assessed the effect of IPT, HAART or both IPT and HAART on tuberculosis incidence in HIV-infected adults in South Africa...
- Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?S D Lawn
The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Int J Tuberc Lung Dis 15:571-81. 2011..Much earlier ART initiation with high coverage is required if ART is to substantially influence the incidence of TB...
- Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort studyKeertan Dheda
Lung Infection and Immunity Unit, Division of Pulmonology and University of Cape Town Lung Institute, Department of Medicine, Cape Town, South Africa
Lancet 375:1798-807. 2010....
- IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infectionAnnalisa Azzurri
Department of Internal Medicine, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
Microbes Infect 7:1-8. 2005..Active TB is associated with increased CXCL10 and PTX3 levels in the plasma. Although not specific for TB, measurement of these proteins may help the monitoring of disease activity and efficacy of therapy...
- HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkersP Sonnenberg
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
Lancet 358:1687-93. 2001..We followed up a cohort of 326 South African mineworkers, who had successfully completed treatment for pulmonary tuberculosis in 1995, to determine the rate and mechanisms of recurrence...
- Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needsAlimuddin Zumla
University College London, Centre for Clinical Microbiology, Division of Infection and Immunity, London, UK
J Infect Dis 205:S228-40. 2012....
- Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosisS Borrell
Division of Mycobacterial Research, Medical Research Council National Institute for Medical Research, London, UK
Int J Tuberc Lung Dis 13:1456-66. 2009..Such increased knowledge will allow for better epidemiological predictions and assist in the development of new tools and strategies to fight drug-resistant TB...
- Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapyAndrew Boulle
School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
JAMA 300:530-9. 2008..Rifampicin-based antitubercular therapy reduces the plasma concentrations of nevirapine and efavirenz. The virological consequences of these interactions are not well described...
- Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projectsEkaterina V Kurbatova
U S Centers for Disease Control and Prevention, International Research and Programs Branch, Division of Tuberculosis Elimination, Atlanta, GA 30333, USA
Tuberculosis (Edinb) 92:397-403. 2012..To prevent treatment default, management of patients who are unemployed, homeless, alcoholic, or have a prison history requires extra measures to insure treatment completion...
- Which new diagnostics for tuberculosis, and when?Frank Cobelens
Department of Global Health, Academic Medical Center and Amsterdam Institute of Global Health and Development, Amsterdam, The Netherlands
J Infect Dis 205:S191-8. 2012..The evidence for both steps should be systematically collected, but each requires different study designs...
- Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosisJuan Carlos Palomino
Mycobacteriology Unit, Institute of Tropical Medicine, Nationalestraat 155, Antwerp 2000, Belgium
Antimicrob Agents Chemother 46:2720-2. 2002..Specificity and sensitivity were excellent. The method is simple, inexpensive, and rapid and might be used with other antituberculosis drugs...
- The diarylquinoline TMC207 for multidrug-resistant tuberculosisAndreas H Diacon
Centre for Clinical Tuberculosis Research, the Department of Science and Technology, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, all in South Africa
N Engl J Med 360:2397-405. 2009..TMC207 potently inhibits drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and shows bactericidal activity in patients who have drug-susceptible pulmonary tuberculosis...
- Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosisCatherine Riou
Division of Immunology, Institute of Infectious Diseases and Molecular Medicine IIDMM, Clinical Laboratory Sciences, University of Cape Town, Cape Town, Western Cape, South Africa
PLoS ONE 7:e36886. 2012..The goal of this study was to evaluate changes in plasma cytokines in patients undergoing treatment for TB as a means of identifying candidate host markers associated with microbiologic response to therapy...
- Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screeningSarah A Stanley
The Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA
ACS Chem Biol 7:1377-84. 2012..This suggests that methodologies currently employed for screening and target identification may lead to a bias in target discovery and that alternative methods should be explored...
- Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysisFaiz A Khan
Montreal Chest Institute, McGill University Health Centre, Montreal, Canada
Clin Infect Dis 50:1288-99. 2010..Patients with human immunodeficiency virus (HIV) infection and tuberculosis have an increased risk of death, treatment failure, and relapse...
- Efflux as a mechanism for drug resistance in Mycobacterium tuberculosisPedro Eduardo Almeida da Silva
Universidade Federal do Rio Grande, Rio Grande, BrazilMycobacteriology Unit, Institute of Tropical Medicine Antwerp, Belgium
FEMS Immunol Med Microbiol 63:1-9. 2011..tuberculosis. This minireview describes the current knowledge on drug efflux in M. tuberculosis...
- Leads for antitubercular compounds from kinase inhibitor library screensSophie Magnet
Global Health Institute, Ecole Polytechnique Federale de Lausanne, CH 1015 Lausanne, Switzerland
Tuberculosis (Edinb) 90:354-60. 2010..Like the BTZ, VI-9376 was shown to act on the essential enzyme decaprenylphosphoryl-β-D-ribose 2'-epimerase, DprE1, required for arabinan synthesis...
- Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatmentA Trajman
Pró reitoria de Saúde, Gama Filho University, Brazil
Int J Tuberc Lung Dis 14:551-9. 2010..Randomised controlled trial of latent tuberculosis infection (LTBI) treatment in 10 clinics in Canada, Saudi Arabia and Brazil...
- Increasing drug resistance in extensively drug-resistant tuberculosis, South AfricaN Sarita Shah
Tugela Ferry Care and Research Collaboration, Tugela Ferry, South Africa
Emerg Infect Dis 17:510-3. 2011..Of 19 patients with extensively drug-resistant TB identified during February 2008-April 2009, 13 (68%) had isolates resistant to all 8 drugs tested. This resistance leaves no effective treatment with available drugs in South Africa...
- Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in ChinaPenghui Shang
Department of Epidemiology and Bio statistics, School of Public Health, Peking University Health Science Centre, Beijing, China
PLoS ONE 6:e21836. 2011..This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China...
- National survey of drug-resistant tuberculosis in ChinaYanlin Zhao
Chinese Center for Disease Control and Prevention, and Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China
N Engl J Med 366:2161-70. 2012..The available information on the epidemic of drug-resistant tuberculosis in China is based on local or regional surveys. In 2007, we carried out a national survey of drug-resistant tuberculosis in China...
- Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South AfricaStephanus Komati
South African National Defence Force, Pretoria, South Africa
AIDS 24:1849-55. 2010..To determine important risk factors for and impact of tuberculosis on survival in HIV-infected patients starting antiretroviral therapy (ART) in South Africa...
- Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004V Leimane
State Agency of Tuberculosis and Lung Diseases, Riga, Latvia
Eur Respir J 36:584-93. 2010..Overall, treatment success among all MDR-TB cases increased over time. Strategies to prevent transmission of XDR-TB and to further improve treatment outcome are crucial for the future of TB control in Latvia...
- PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO releaseRamandeep Singh
Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
Science 322:1392-5. 2008..Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug. Thus, these compounds may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system...
- LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statementU Mack
Lovisenberg Diakonale Sykehus, Oslo, Norway
Eur Respir J 33:956-73. 2009..In summary, the main issue regarding testing is to restrict it to those who are known to be at higher risk of developing tuberculosis and who are willing to accept preventive chemotherapy...
- Hepatotoxicity of pyrazinamide: cohort and case-control analysesKwok C Chang
Tuberculosis and Chest Service, Centre for Health Protection, Department of Health, Hong Kong, China
Am J Respir Crit Care Med 177:1391-6. 2008..Relatively little is known about the hepatotoxicity of pyrazinamide...
- Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosisMontserrat Garrigó
Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Av Sant Antoni M Claret, 167, 08025 Barcelona, Spain
J Clin Microbiol 45:1766-70. 2007..In general, the MB/BacT and BACTEC MGIT 960 systems showed good performance for susceptibility testing with first-line antituberculosis drugs...
- The impact of age on the demographic, clinical, radiographic characteristics and treatment outcomes of pulmonary tuberculosis patients in TaiwanC S Wang
Dept of Internal Medicine, Kaohsiung Municipal Hsiao Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC
Infection 36:335-40. 2008..The aim of this study was to investigate the impact of age on the demographic, clinical, radiographic characteristics, and treatment outcomes of pulmonary TB patients in Taiwan...
- GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysisD I Ling
Dept of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Avenue West, Montreal, QC H3A 1A2, Canada
Eur Respir J 32:1165-74. 2008..While specificity is excellent for isoniazid, sensitivity estimates were modest and variable. Together with data from demonstration projects, the meta-analysis provides evidence for policy making and clinical practice...
- The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutolA Telenti
Institute for Medical Microbiology, University of Bern, Switzerland
Nat Med 3:567-70. 1997..Further characterization of these proteins might provide information on targets for new chemotherapeutic agents and might help development of diagnostic strategies for the detection of resistant M. tuberculosis...
- Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcomeTimothy H Holtz
Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
Ann Intern Med 144:650-9. 2006....
- BIOSYNTHESIS OF ANTITUBERCULAR NONRIBOSOMAL PEPTIDEST Zabriskie; Fiscal Year: 2006..will yield valuable information that will be translated into novel molecular tools for generating new antitubercular agents. The knowledge and methods that arise from these studies will be directly applicable to expanding the ..
- A Fluorescence Polarization Assay for Fatty Acid Adenylating EnzymesCourtney C Aldrich; Fiscal Year: 2012..of the FadD's play in lipid metabolism and could additionally lead to the development of new class of antitubercular agents. Toward this goal we propose to develop a fluorescence polarization assay amenable to high throughput ..
- Design of antituberculosis agents that target siderophore biosynthesisCourtney C Aldrich; Fiscal Year: 2013..The proposed research is expected to validate siderophore biosynthesis as new antibacterial target, which may lead to the development of a new class of antitubercular agents.
- MECHANISM BASED INHIBITION OF M TUBERCULOSIS ENZYMESJohn S Blanchard; Fiscal Year: 2012..With the emergence and spread of multi-drug resistant strains of the bacteria, new targets must be identified and developed to which new inhibitors can be identified, allowing new therapeutically useful drugs to be developed. ..
- ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONSEvan D Kharasch; Fiscal Year: 2012..It is also relevant to creating a better basic understanding of how drugs enter the brain and are inactivated by the body, and how therapeutic drugs affect healthy and ill individuals. ..
- Gyrase B Inhibitors for Mycobacterium TuberculosisPeter B Madrid; Fiscal Year: 2013..The development of a shorter, more effective treatment regimen will increase patient compliance and thereby slow down the emergence of drug resistance and protect vulnerable populations worldwide. ..
- Advancing lead dipiperidine compound into preclinical developmentMarina Protopopova; Fiscal Year: 2009..Completion of these Specific Aims will provide vital data in support of development of SQ609 as an antitubercular and a firm rationale for determining whether or not to advance SQ609 into the extensive preclinical testing. ..
- Targeting MDR-TBRobert C Reynolds; Fiscal Year: 2010..be to bring data for a select set of compounds that have promise for new drug discovery into the public and commercial domain for further advancement towards new antitubercular agents to treat drug resistant disease.
- Low Cost Monitoring Strategy to Optimize Tuberculosis Treatment in ChildrenSusan M Abdel-Rahman; Fiscal Year: 2012..As a research tool, DBS technology will allow investigators to validate dose-exposure relationships in populations that would otherwise never be represented in pharmacokinetic studies. ..
- Porins of Mycobacterium tuberculosisMichael Niederweis; Fiscal Year: 2009..These studies will not only be essential for the design of new TB drugs, but will also be of fundamental interest for our understanding of nutrient uptake by M. tuberculosis. ..
- AEROSOL FOR ANTITUBERCULAR DRUG DELIVERYAnthony Hickey; Fiscal Year: 1999..Therapeutic targeting may be demonstrated by delivering microparticles containing antitubercular agents as aerosols to macrophages in the lungs of diseased animals and evaluating their action...
- Inhibitor of FtsZ Polymerization in M. tuberculosisRobert Reynolds; Fiscal Year: 2004DESCRIPTION (Provided by the applicant): Development of new antitubercular agents is of critical importance worldwide...
- RIFAMYCIN BIOSYNTHETIC ANALOGSChaitan Khosla; Fiscal Year: 2003..6) Engineer the rifamycin gene cluster for overproduction of rifamycin B and eventual rifamycin analogs. (7) If necessary, move some of the rifamycin gene cluster into Streptomyces lividans to facilitate aims 4 - 6. ..
- Specific target of NO-mediated damage in M tuberculosisKyu Rhee; Fiscal Year: 2007..tuberculosis offers the promise of developing novel antitubercular agents that augment or mimic the natural immune response to infection with M...
- Pseudopteroxazole and Related Antitubercular AgentsMichael Harmata; Fiscal Year: 2007The goals of this work are to develop syntheses of antitubercular agents based on natural product leads...
- ESSENTIAL GENES OF THE MYCOBACTERIAGraham Hatfull; Fiscal Year: 1999..Many of the essential genes identified will be potential targets for antimycobacterial agents and will serve as an initiation point for the rationale design of novel antitubercular drugs. ..
- Total Synthesis of Tubelactomicin A and KijanolideTONY TRULLINGER; Fiscal Year: 2004..Macrolactonization will afford the natural product. ..
- Thioesterase Inhibitors of Mycolic Acid Biosynthesis as Antitubercular AgentsCourtney Aldrich; Fiscal Year: 2008..Additionally, this strategy may be adapted to inhibit critical PKSs from other pathogenic microorganisms. [unreadable] [unreadable] [unreadable]..
- BCG + hsp, a New Tuberculosis VaccineBoris Nikonenko; Fiscal Year: 2003..We will also examine the antibiotic sensitivity of this rBCGdeltahspR to 10 commonly used TB drugs to ensure that the genetic manipulations performed have not made it less sensitive to drug treatment. ..
- TB/HIV RISK REDUCTION WITH HOMELESS AND DRUG ADDICTEDAdeline Nyamathi; Fiscal Year: 2002....
- Rapid Detection of Mycobacterium tuberculosisSusan Dorman; Fiscal Year: 2007..unreadable] [unreadable] Relevance: Results of these studies will improve our understanding of the laboratory performance and clinical benefit of this test, and lead to improved detection and treatment of TB. [unreadable] [unreadable]..
- Domoic Acid and Neonatal Microglia ActivationAlejandro Mayer; Fiscal Year: 2004..activated microglia cells and their mediators play in DOM-induced excitotoxic neuronal injury and thus contribute to potential novel approaches for the therapy of the neuropathology associated with Amnesic Shellfish Poisoning in humans ..
- Fluoroquinolone Resistance in M. TuberculosisTimothy R Sterling; Fiscal Year: 2010..tuberculosis would clarify whether fluoroquinolones are indeed a viable option for the first-line treatment of tuberculosis, and how best to preserve their usefulness against tuberculosis. ..
- Epidemiology of multidrug-resistant tuberculosis in PeruMercedes Becerra; Fiscal Year: 2008..tuberculosis strains. Results will serve to guide basic research in tuberculosis diagnostics and therapeutics. ..
- Structure Function Analysis of TB PyrazinamidaseYing Zhang; Fiscal Year: 2005..These studies will provide important information about mechanisms of PZA action and resistance and may help design new antituberculosis drugs. ..
- Mycobacterium tuberculosis cell wall virulence factorsSusan Dorman; Fiscal Year: 2004..Finally, new information from the proposed self-contained pilot studies will serve as the foundation for future comprehensive dissection of macrophage response pathways affected by specific cell wall components. ..
- IRON REGULATION & VIRULENCE--MYCOBACTERIUM TUBERCULOSISYUKARI MANABE; Fiscal Year: 2003..Elucidation of this iron-dependent IdeR regulon may lead to the identification of virulence determinants, and novel antigens for vaccines and therapeutics. ..
- MACROPHAGES, DENDRITIC CELLS AND PATHOGENSCarl Nathan; Fiscal Year: 2007..Cores provide for BSL3 wet lab and mouse work; microarray analysis of gene expression; computation and comparison of gene expression results; and high throughput screening of chemical libraries. ..
- Sample Processing Cartridges for Rapid PCR TB DetectionDavid Alland; Fiscal Year: 2008..The system will then be retested using a large number of clinical sputum specimens. Finally, we will develop complete documentation on the assay including production, and development reports. [unreadable] [unreadable] [unreadable]..
- Towards drugs that prevent resistance to the HIV OI, TBDavid Alland; Fiscal Year: 2006..if embB306 mutations affect biosynthesis of LAM, capped LAM, arabinogalactan (AG) or other cell wall components in the presence and absence of EMB. ..
- Detection of Select Agents in Single-Well AssaysDavid Alland; Fiscal Year: 2007..3. To develop PCR assays that utilize "color-triplet coding" to uniquely label as many as 56 different species-specific molecular beacons. ..
- POPULATION BASED INVESTIGATIONS OF TUBERCULOSISDavid Alland; Fiscal Year: 2004..Studies of these sequence variations in clinical strains will be used to determine the associations between specific mutations and the phenotypes of infectivity and virulence. ..
- TUBERCULOSIS GENOTYPING AND EVOLUTIONARY CONSORTIUMDavid Alland; Fiscal Year: 2005..4) To identify and validate an informative set of SNPs for worldwide evolutionary and epidemiological analyses. ..
- AGING AND IMMUNITY IN TUBERCULOSISIan Orme; Fiscal Year: 2002....
- Oxidative Stress and the Pathogenesis of Sarcopenia and Disability in Older WomenRichard Semba; Fiscal Year: 2008..AGEs are a potentially modifiable risk factor, as circulating AGEs can be lowered by dietary modification and by pharmacological intervention. ..
- Mouse Strain dependent innate resistance to intestinal amebiasisEric Houpt; Fiscal Year: 2009....
- COCAINE, ALCOHOL, AND COCAETHYLENE--CLINICAL EFFECTSElinore McCance Katz; Fiscal Year: 2002..In total, these studies should provide significant contributions to the current state of knowledge regarding the epidemiology of cocaine-alcohol abuse and treatment of these disorders. ..
- Disulfiram Interactions With HIV Medications: Clinical ImplicationsElinore F McCance Katz; Fiscal Year: 2010....
- Clinical Trial of Short Course vs. INH for LTBI in JailMary White; Fiscal Year: 2008..Analysis of completion of therapy and cost-effectiveness of this regimen will provide important information for policy change in the way LTBI is managed in jail. ..
- Hepcidin and the pathogenesis of anemia in older adults.Richard D Semba; Fiscal Year: 2010..This study should provide new insight into the epidemiology and biological mechanisms of anemia among older adults and help identify strategies aimed at the prevention and treatment of anemia. ..
- Cell Biology of Mycobacterium tuberculosis InfectionDavid G Russell; Fiscal Year: 2010..tuberculosis. We propose determining how the bacterium's metabolism is realigned to access these carbon sources. ..
- Interaction of Alcohol and HAART in HIV/AIDS and HIV/AIDS and HCV CoinfectionElinore F McCance Katz; Fiscal Year: 2011..The proposed studies will inform clinical treatment of comorbid HIV/AIDS, Hepatitis C and alcohol use/abuse leading to improved clinical outcomes and reduced risk of HIV transmission. ..
- CATALASE-PEROXIDASE CATALYSIS IN ANTIBIOTIC ACTIVATIONRICHARD MAGLIOZZO; Fiscal Year: 2002..The results of the proposed studies will advance a detailed understanding of the action of a first line antibiotic in current use to treat tuberculosis. ..
- Regulated expression of B. burgdorferi virulence genesFELIPE CARDENAS CABELLO; Fiscal Year: 2010..burgdorferi. These tools will be used to identify genes that are potentially responsible for this organism's virulence and which could be targets for new vaccines and antibiotics against Lyme disease. ..
- DRUGS AND DELIVERY SYSTEMS FOR OPPORTUNISTIC INFECTIONSMarvin Miller; Fiscal Year: 2002....
- RECOMBINANT BCG MALARIA VACCINESWilliam Jacobs; Fiscal Year: 2001..The immunization studies are designed to test the recombinant BCG's expressing MSP-1 for protection and their abilities to induce a priming immunization that can confer protection upon infection with the malarial parasites. ..
- Improving Health Outcomes for Released HIV+ PrisonersFrederick Altice; Fiscal Year: 2007..unreadable] [unreadable] [unreadable] [unreadable]..
- Prevalence, risk factors and consequences of complex M. Tuberculosis infectionsTheodore Cohen; Fiscal Year: 2010..The overall goal of this study is to learn more about the natural history of TB and to use this knowledge to improve the health of individuals and their communities. ..
- Genetic approaches to protein-protein interactions mediating antibiotic resistancCHRISTOPHER KRISTICH; Fiscal Year: 2009....
- Development of a Novel Strategy of Adjuvant DiscoveryDavid Russell; Fiscal Year: 2009..It is anticipated that this final aim will develop into a new grant application that will enable us to test the effectiveness of a range of microbial products for their efficacy as adjuvants. ..
- The role of NK cells in human M. Tuberculosis infectionRamakrishna Vankayalapati; Fiscal Year: 2009..These findings will facilitate development of immunomodulatory strategies to boost the immune response to M. tuberculosis, including multidrug-resistant tuberculosis. ..
- Mucosal immune regulation in murine amebic colitisEric Houpt; Fiscal Year: 2007..The comprehensive approach in training and research laid out in this research proposal will guide the applicant towards his goal of being an independent investigator in immunoparasitology. ..
- Zeiss LSM510 Meta Confocal MicroscopeDavid Russell; Fiscal Year: 2007..These data will extend ongoing, NIH-funded programs for identification of new drug targets, vaccines and adjuvants. [unreadable] [unreadable] [unreadable]..
- MOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSISWilliam Jacobs; Fiscal Year: 2003..Ultimately, the knowledge of mycobacterial virulence and persistence factors should lead to the development of novel drugs, vaccines, and immunotherapies to control tuberculosis. ..
- Neurodevelopment and HIV/AIDSAnnelies Van Rie; Fiscal Year: 2005....
- Real-time PCR diagnostic kit for Giardia and CryptosporidiumEric Houpt; Fiscal Year: 2006..A Phase II application is anticipated to validate the final diagnostic test product against immunoassay for an FDA 501 (k) medical device application. [unreadable] [unreadable] [unreadable]..
- DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSISIan Orme; Fiscal Year: 2006..The proposed work will draw upon the broad expertise of various members of the Mycobacteria Research Laboratories at Colorado State University, as well as several eminent consultants and advisers. ..
- Bioactive Compounds from Acylnitroso CycloadductsMarvin Miller; Fiscal Year: 2006..abstract_text> ..
- Evaluation of MDR-TB Treatment Strategies in Lima, PeruSonya Shin; Fiscal Year: 2006..abstract_text> ..
- Randomized Trial of High-Dose Rifampin in Patients with New, Smear-Positive TBCarole Mitnick; Fiscal Year: 2007..Moreover, this trial will contribute to the existing evidence base about possible surrogate endpoints, thereby simplifying future trials of investigational new anti-tuberculosis [unreadable] [unreadable] [unreadable]..
- Multiplex bead-PCR diagnosis for AIDS diarrheaEric Houpt; Fiscal Year: 2007..Finally, syndrome-based multiplex diagnosis is the platform of the future for clinical microbiology, and if this assay works on stool it should work on sputum, blood, or spinal fluid. [unreadable] [unreadable] [unreadable]..
- Mathematically modeling the transmission and control of extensively drug resistanSanjay Basu; Fiscal Year: 2008..The goal of this project is to determine how to reduce XDR tuberculosis incidence, using mathematical models of its transmission. [unreadable] [unreadable] [unreadable]..
- Opioids & HIV Medications: Interactions in Drug AbusersElinore McCance Katz; Fiscal Year: 2008..Drug interaction studies of the type proposed have been identified as a priority research area for NIDA because of their importance to optimizing the clinical care of HIV disease in opioid dependent patients. ..
- Pulmonary Hypertension and the Hypoxic Response in SCDVictor Gordeuk; Fiscal Year: 2008..Aim 3. Using micro array analysis and high throughput genotyping, examine patterns of gene expression and candidate gene polymorphisms of the HIF-mediated hypoxic response in SCD and CP patients with and without PHTN. ..
- COCAETHYLENE COCAINE AGONIST THERAPY/TOLERANCE INDUCTIONElinore McCance Katz; Fiscal Year: 2002..Positive findings from these studies could be followed in future studies with clinical trials to assess the efficacy of this class of drugs in the treatment of cocaine dependence. ..
- INH-induced lysis of the HIV opportunistic infection, M. tuberculosisWilliam Jacobs; Fiscal Year: 2008..The knowledge gained by this work will lead to the identification of novel drug targets, strategies to overcome tolerance, and more effective treatments for tuberculosis. ..
- Training in Translational Lung ResearchNeil Schluger; Fiscal Year: 2008..abstract_text> ..
- Molecular approaches for understanding TB dynamicsTheodore Cohen; Fiscal Year: 2008..It is our hope that better analytic techniques will allow for more accurate assessments of treatment and prevention. [unreadable] [unreadable]..
- ADJUNCT VITAMIN A THERAPY FOR TUBERCULOSIS AND HIV/AIDSRichard Semba; Fiscal Year: 2005....
- Howard-CNMC Sickle Cell Disease Clinical CenterVictor Gordeuk; Fiscal Year: 2008..A major feature of both sickle cell programs has always been continuity of care and participation in collaborative research. ..
- Metabolism of M. tuberculosis: New Targets for MDR TBDavid Russell; Fiscal Year: 2004..abstract_text> ..